Učitavanje...
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma
PURPOSE: Lestaurtinib (CEP-701), a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases, has undergone early phase clinical evaluation in children with relapsed neuroblastoma. We studied the interaction of CEP-701 with isotretinoin (13cRA) and fenretinide (...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4135359/ https://ncbi.nlm.nih.gov/pubmed/21484309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1623-y |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|